| 000 | 01583 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517115151.0 | ||
| 264 | 0 | _c20170428 | |
| 008 | 201704s 0 0 eng d | ||
| 022 | _a1868-7083 | ||
| 024 | 7 |
_a10.1186/s13148-016-0264-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGraça, Inês | |
| 245 | 0 | 0 |
_aEpigenetic modulators as therapeutic targets in prostate cancer. _h[electronic resource] |
| 260 |
_bClinical epigenetics _c2016 |
||
| 300 |
_a98 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aDNA (Cytosine-5-)-Methyltransferases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aDNA Methylation _xdrug effects |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aEpigenesis, Genetic _xdrug effects |
| 650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xdrug effects |
| 650 | 0 | 4 |
_aHistone Deacetylase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aHistones _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aPereira-Silva, Eva | |
| 700 | 1 | _aHenrique, Rui | |
| 700 | 1 | _aPackham, Graham | |
| 700 | 1 | _aCrabb, Simon J | |
| 700 | 1 | _aJerónimo, Carmen | |
| 773 | 0 |
_tClinical epigenetics _gvol. 8 _gp. 98 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s13148-016-0264-8 _zAvailable from publisher's website |
| 999 |
_c26438382 _d26438382 |
||